Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Gaithersburg, United States. In Neoplasia, Aug 2015
Based on the previously described roles of doxorubicin in immunogenic cell death, both doxorubicin and liposomal doxorubicin (Doxil) were evaluated for their ability to boost the antitumor response of different cancer immunotherapies including checkpoint blockers (anti-PD-L1, PD-1, and CTLA-4 mAbs) and TNF receptor agonists (OX40 and GITR ligand fusion proteins) in syngeneic mouse models.
Co-stimulatory molecules in and beyond co-stimulation - tipping the balance in atherosclerosis?
München, Germany. In Thromb Haemost, 2011
In particular, the contribution of CD28/CD80/CD86/CTLA4, ICOS/ICOSL, PD-1/PDL-1/2, TRAF, CD40/CD154, OX40/OX40L, CD137/CD137L, CD70/CD27, GITR/GITRL, and LIGHT to arterial disease is reviewed.